In vitro assay demonstrates potent urease enzyme inhibition by novel triazole-bearing benzimidazole derivatives, indicating potential for treating urease-associated bacterial infections.
A new series of benzimidazoles including triazole and thiosemicarbazide moieties was synthesized and their urease inhibition studies were evaluated according to the method of Van Slyke and Archibald. Especially triazole derivatives have effective inhibition activities between 0.04±0.026 and 0.26±0.042 µM IC50 values. The best antiurease activities with IC50 0.04±0.026 and 0.06±0.033 µM belongs to 5-[(5,6-dichloro-1H-benzimidazol-1-yl)methyl]-4-nitrophenyl-4H-1,2,4-triazole-3-thiol and 2-[(2-benzyl-5,6-dichloro-1H-benzimidazol-1-yl)acetyl]-N-(4-nitrophenyl)hydrazinecarbothioamide, respectively.
No takes yet. Share an insight, caveat, or question.
Akyüz et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: